Fig. 5: Comparisons of most frequently used triplet regimens on post-progression survival. | Blood Cancer Journal

Fig. 5: Comparisons of most frequently used triplet regimens on post-progression survival.

From: Second- and third-line treatment strategies in multiple myeloma: a referral-center experience

Fig. 5

A Time to next treatment from first relapse (TTNT). B Overall survival from first relapse (OS). CI confidence interval, CYBORD cyclophosphamide-bortezomib-dexamethasone, Dara-RD daratumumab-lenaliodmide-dexamethasone, HR hazard ratio, KRD carfilzomib-lenalidomide-dexamethasone, VRD bortezomib-lenalidomide-dexamethasone.

Back to article page